ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Abacavir Sulfate, Lamivudine And Zidovudine, and what generic alternatives are available?
Abacavir Sulfate, Lamivudine And Zidovudine is a drug marketed by Lupin Ltd and is included in one NDA.
The generic ingredient in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE?
- What are the global sales for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE?
- What is Average Wholesale Price for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE?
Summary for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 3 |
| Clinical Trials: | 6 |
| DailyMed Link: | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE at DailyMed |
Recent Clinical Trials for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Gilead Sciences | Phase 3 |
| Harvard School of Public Health (HSPH) | Phase 2 |
| Harvard School of Public Health | Phase 2 |
See all ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE clinical trials
Pharmacology for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
US Patents and Regulatory Information for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | abacavir sulfate; lamivudine; zidovudine | TABLET;ORAL | 202912-001 | Dec 5, 2013 | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
